June 27, 2023 10:11 AM EDTUpdated 10:26 AM

FDA approves first of two UCB myasthenia gravis drugs, following Alexion and argenx’s lead

Kyle LaHucik

Senior Reporter

The FDA approved UCB’s generalized myasthenia gravis treatment Rystiggo, with the Belgian drugmaker saying it is the first drug to get OK’d for the two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves first of two UCB myasthenia gravis drugs, following Alexion and argenx’s lead

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA ap­proves first of two UCB myas­the­nia gravis drugs, fol­low­ing Alex­ion and ar­genx’s lead

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA approves first of two UCB myasthenia gravis drugs, following Alexion and argenx’s lead

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm